Beijing Biostar Pharmaceuticals (HKG:2563) received approval from the U.S. Food and Drug Administration (FDA) for its international multi-center Phase II/III registration clinical study for Utidelone Capsules, according to a Thursday filing with the Hong Kong bourse.
UTD2 with capecitabine and oxaliplatin for first-line treatment of advanced or metastatic gastric cancer in PD-L1-negative patients, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.